Revolution Medicines to present phase 3 pancreatic cancer trial data at ASCO

April 21, 2026 11:23 AM

Revolution Medicines Inc. (NASDAQ: RVMD) announced that results from its Phase 3 RASolute 302 clinical trial will be presented during ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found